Quantcast
Last updated on April 18, 2014 at 15:19 EDT

Latest Apolipoprotein E Stories

2013-02-14 10:28:53

Healthy menopausal women carrying a well-known genetic risk factor for Alzheimer's disease showed measurable signs of accelerated biological aging, a new study has found. However, in carriers who started hormone therapy at menopause and remained on that therapy, this acceleration was absent, the researchers said. Hormone therapy for non-carriers of the risk factor, a gene variant called ApoE4, had no protective effect on their biological aging. "This shows that ApoE4 is contributing to...

2012-12-02 05:01:39

innerQuest Psychiatry is a psychiatrist & psychologist group in Asheville, NC composed of Dr. Leonard Cruz, Dr. Steven Buser and Dr. Richard Smoot. In this article, Dr. Cruz reviews recent evidence of a cancer drug showing hopeful signs for new treatment in Alzheimers disease. Asheville, NC (PRWEB) December 01, 2012 innerQuest Psychiatry is a psychiatrist & psychologist group in Asheville, NC composed of Dr. Leonard Cruz, Dr. Steven Buser and Dr. Richard Smoot. In this article,...

Gene Discovered That Triples Risk Of Alzheimer's Disease
2012-11-15 15:08:47

Connie K. Ho for redOrbit.com — Your Universe Online A group of researchers from 44 different institutions around the world, including scientists from the Mayo Clinic, the University of Toronto, and the University of Nottingham, recently discovered a gene that almost triples the risk of developing Alzheimer´s disease. The international group of scientists utilized the Nottingham ARUK DNA bank, one of the biggest collections of DNA pooled from Alzheimer´s patients....

2012-10-16 10:55:00

A new study shows that having a high amount of beta amyloid or "plaques" in the brain associated with Alzheimer's disease may cause steeper memory decline in mentally healthy older people than does having the APOE É›4 allele, also associated with the disease. The study is published in the October 16, 2012, print issue of Neurology®, the medical journal of the American Academy of Neurology. "Our results show that plaques may be a more important factor in determining which...

2012-08-06 10:25:04

NEW BRUNSWICK, N.J., Aug. 6, 2012 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) today announced that phase 3 clinical development of bapineuzumab intravenous (IV) in mild-to-moderate Alzheimer's disease is being discontinued. Janssen Alzheimer Immunotherapy (Janssen AI), a subsidiary of Johnson & Johnson, is a partner with Pfizer in the Alzheimer's Immunotherapy Program (AIP). The Joint Steering Committee for the AIP has decided to discontinue the development of...

Pfizer Drug Study Falls Short For Alzheimer’s
2012-07-24 08:50:54

Lawrence LeBlond for redOrbit.com - Your Universe Online In one of two late-stage trials conducted by Pfizer, an experimental Alzheimer´s drug failed to slow the disease´s progress, but the pharma said on Monday that it will continue to study the drug´s effect on the other group. The injected drug bapineuzumab, being tested through a partnership with Johnson & Johnson, didn´t slow mental or functional decline in patients with mild or moderate Alzheimer´s...

2012-07-18 10:26:11

VANCOUVER, British Columbia, July 18, 2012 /PRNewswire-USNewswire/ -- In April 2011, the U.S. National Institute on Aging (NIA) and the Alzheimer's Association published new criteria and guidelines for the diagnosis of Alzheimer's disease. These guidelines separate the progression of Alzheimer's into three phases: (1) pre-clinical (or pre-symptomatic) Alzheimer's disease, (2) mild cognitive impairment (MCI) due to Alzheimer's disease, and (3) Alzheimer's disease dementia. Phases (1) and (2)...

2012-07-17 06:25:37

VANCOUVER, British Columbia, July 17, 2012 /PRNewswire-USNewswire/ -- With FDA approval of a brain amyloid imaging compound in early 2012 and the expected start in 2012 and 2013 of three clinical trials in people with pre-symptomatic Alzheimer's disease, issues around disclosure of dementia risk status are becoming more urgent. Several research efforts reported today at the Alzheimer's Association International Conference® 2012 (AAIC® 2012) describe the creation and evaluation of new...

2012-07-12 02:27:51

LONDON, July 12, 2012 /PRNewswire/ -- AstraZeneca and Dr. Steven Paul of Weill Cornell Medical College today announced a first of its kind research alliance that brings four leading academic research laboratories together with AstraZeneca to study a major risk factor for Alzheimer's disease, the apolipoprotein E4 genotype (ApoE). Members of the newly established collaboration with AstraZeneca, called the A5 alliance, include Dr. Paul of the Helen and Robert Appel Alzheimer's Disease Research...

2012-06-18 02:28:32

NEW YORK, June 18, 2012 /PRNewswire/ -- There is a well-known link between Alzheimer's disease and a gene called ApoE4. In fact, people who carry two copies of the gene have approximately 8 to 10 times the risk of getting Alzheimer's than those who do not have the gene. Up to now though, little was known about how ApoE4 contributed to Alzheimer's devastating deterioration of the brain. However, in a ground breaking study published in Nature and financed by the Alzheimer's Association and The...